Eleanor Young

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

This study identifies NSD2 as a critical component of the AR neo-enhanceosome in prostate cancer, showing its role in AR enhancer circuitry and tumor progression.

This study identifies a therapeutic vulnerability in POU2F-POU2AF-driven cancers by showing that targeting the mSWI/SNF complex with a PROTAC degrader reduces tumor growth in preclinical models.

This paper develops an orally bioavailable PROTAC degrader of mSWI/SNF ATPases for prostate cancer and identifies resistance mechanisms through long-term treatment.

The paper introduces a linked-pair long-read sequencing strategy for targeted resequencing, enabling efficient enrichment of genomic regions with haplotype information.

The paper uses optical mapping to analyze subtelomere structure and variation across 154 human genomes, identifying novel haplotypes and population-specific trends.